Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
398,346
-
Share change
-
+31,247
-
Total reported value
-
$3,358,000
-
Put/Call ratio
-
290%
-
Price per share
-
$8.43
-
Number of holders
-
11
-
Value change
-
+$295,127
-
Number of buys
-
9
-
Number of sells
-
3
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q4 2020
As of 31 Dec 2020,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
398,346 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, Golden Green, Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, UBS Group AG, CITADEL ADVISORS LLC, BANK OF AMERICA CORP /DE/, MORGAN STANLEY, SIMPLEX TRADING, LLC, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, and HighMark Wealth Management LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.